The carried drug managed to alter Pin1 cancer-driving pathways by inducing proteasome-dependent degradation of Pin1, the delivery system as a whole proving to be an effective alternative for curbing ovarian tumor growth in vivo. The gene discussed is PIN1; the disease is ovarian neoplasm.